文献速递肝病

血浆氨水平可预测临床稳定的肝硬化门诊患者发生肝脏相关并发症住院及死亡

Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis.
PubMed 文献 · J Hepatol · 2022-07-22

研究纳入3个独立肝病中心的754例临床稳定肝硬化门诊患者,评估基线血氨校正至正常上限(AMM-ULN)与肝脏相关并发症住院及死亡的关系,并在130例独立三级肝病中心患者中进行外部验证。结果显示AMM-ULN是肝脏相关并发症住院(HR 2.13;95%CI 1.89-2.40;p<0.001)和死亡(HR 1.45;95%CI 1.20-1.76;p<0.001)的独立预测因素,1年肝脏相关并发症的AUROC为77.9%,优于传统严重度评分。

要点

  • AMM-ULN是临床稳定肝硬化门诊患者肝脏相关并发症住院和死亡的独立预测因素。
  • AMM-ULN预测1年肝脏相关并发症的AUROC为77.9%,高于传统严重度评分。
  • 以训练集最佳截断值1.4分组,高、低AMM-ULN组间并发症和死亡率差异均有统计学意义(p<0.001)。

核心结论

  • 氨是临床稳定肝硬化门诊患者肝脏相关并发症住院和死亡的独立预测因素,预测并发症方面优于传统预后评分。

研究设计与样本

  • 前瞻性队列研究,纳入来自3个独立肝病中心的754例临床稳定肝硬化门诊患者,基线氨水平校正至参考实验室正常上限(AMM-ULN)。
  • 采用快速统一随机森林的多变量竞争风险脆弱模型预测并发症和死亡,并用独立三级肝病中心130例肝硬化患者的前瞻性数据进行外部验证。

主要发现

  • 共260例(35%)患者因肝脏相关并发症住院。
  • 多变量分析中,AMM-ULN是肝脏相关并发症的独立预测因素(HR 2.13;95%CI 1.89-2.40;p<0.001)。
  • 多变量分析中,AMM-ULN是死亡的独立预测因素(HR 1.45;95%CI 1.20-1.76;p<0.001)。
  • AMM-ULN预测1年肝脏相关并发症的AUROC为77.9%,高于传统严重度评分。
  • 以训练集最佳截断值1.4分组,高、低AMM-ULN组间并发症和死亡的生存差异均有统计学意义(p<0.001)。

关键数值与推荐

  • AMM-ULN预测肝脏相关并发症的HR为2.13(95%CI 1.89-2.40;p<0.001)。
  • AMM-ULN预测死亡的HR为1.45(95%CI 1.20-1.76;p<0.001)。
  • AMM-ULN预测1年肝脏相关并发症的AUROC为77.9%。
  • 训练集最佳截断值为1.4。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hyperammonaemia is central in the pathogenesis of hepatic encephalopathy. It also has pleiotropic deleterious effects on several organ systems, such as immune function, sarcopenia, energy metabolism and portal hypertension. This study was performed to test the hypothesis that severity of hyperammonaemia is a risk factor for liver-related complications in clinically stable outpatients with cirrhosis. METHODS: We studied 754 clinically stable outpatients with cirrhosis from 3 independent liver units. Baseline ammonia levels were corrected to the upper limit of normal (AMM-ULN) for the reference laboratory. The primary endpoint was hospitalisation with liver-related complications (a composite endpoint of bacterial infection, variceal bleeding, overt hepatic encephalopathy, or new onset or worsening of ascites). Multivariable competing risk frailty analyses using fast unified random forests were performed to predict complications and mortality. External validation was carried out using prospective data from 130 patients with cirrhosis in an independent tertiary liver centre. RESULTS: Overall, 260 (35%) patients were hospitalised with liver-related complications. On multivariable analysis, AMM-ULN was an independent predictor of both liver-related complications (hazard ratio 2.13; 95% CI 1.89-2.40; p <0.001) and mortality (hazard ratio 1.45; 95% CI 1.20-1.76; p <0.001). The AUROC of AMM-ULN was 77.9% for 1-year liver-related complications, which is higher than traditional severity scores. Statistical differences in survival were found between high and low levels of AMM-ULN both for complications and mortality (p <0.001) using 1.4 as the optimal cut-off from the training set. AMM-ULN remained a key variable for the prediction of complications within the random forests model in the derivation cohort and upon external validation. CONCLUSION: Ammonia is an independent predictor of hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis and performs better than traditional prognostic scores in predicting complications. LAY SUMMARY: We conducted a prospective cohort study evaluating the association of blood ammonia levels with the risk of adverse outcomes in 754 patients with stable cirrhosis across 3 independent liver units. We found that ammonia is a key determinant that helps to predict which patients will be hospitalised, develop liver-related complications and die; this was confirmed in an independent cohort of patients.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Tranah TH, Ballester MP, Carbonell-Asins JA, et al. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis. J Hepatol. 2022. PMID: 35872326. doi:10.1016/j.jhep.2022.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。